

**7-5/2013/EU/WC-0218**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organisation**  
**(International Cell)**

FDA Bhawan, Kotla Road  
New Delhi-110002

Dated:

**29 JUN 2022**

To

M/s. Supriya Lifescience Ltd.,  
A-5/2, Lote Parshuram Industrial Area,  
MIDC, Tal-Khed, Dist. Ratnagiri-415 722  
Maharashtra, India

**SUB: - Written Confirmation of M/s. Supriya Lifescience Ltd., A-5/2, Lote Parshuram Industrial Area, MIDC, Tal-Khed, Dist. Ratnagiri-415 722, Maharashtra, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-reg.**

Sir,

Please refer to your online application no. WC/RE/2022/2338 submitted to CDSCO, West Zone and the recommendation received from DDC (I), West Zone Mumbai on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non-Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.

8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid upto
01	28	29 JUN 2022	02/07/2025
02	03	29 JUN 2022	02/07/2025

Yours faithfully,



(Dr. V.G Somani)  
Drugs Controller General (India)





Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Supriya Lifescience Ltd.,  
A-5/2, Lote Parshuram Industrial Area,  
MIDC, Tal-Khed, Dist. Ratnagiri-415 722  
Maharashtra, India
2. Manufacturer's licence number: 25-KD/129, 28-KD/156 and 25F-KD/10

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use  
List of API(s):

As per list annexed

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 09.08.2021 & 10.08.2021

The Written Confirmation remains valid until: 02/07/2025

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

**Address of the issuing regulatory authority:** Central Drugs Standard Control Organisation  
FDA Bhawan, Kotla Road,  
New Delhi- 110 002, India

**Name and function of responsible person:** Dr. V.G. Somani,  
Drugs Controller General (India)

**E-mail:** dci@nic.in,  
**Telephone no.:** +91-11-23236965  
**Fax no.:** +91-11-23236973

Signature

29 JUN 2022

Stamp of the authority and date







Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:

M/s. Supriya Lifescience Ltd.,  
A-5/2, Lote Parshuram Industrial Area,  
MIDC, Tal-Khed, Dist. Ratnagiri-415 722  
Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Albuterol Sulphate USP	Manufacturing & Packing
2.	Bupropion HCl USP	Manufacturing & Packing
3.	Bisoprolol Fumarate BP/EP	Manufacturing & Packing
4.	Cetirizine Dihydrochloride BP/EP	Manufacturing & Packing
5.	Cetirizine Hydrochloride USP	Manufacturing & Packing
6.	Chlorphenamine Maleate BP/EP	Manufacturing & Packing
7.	Chlorpheniramine Maleate USP	Manufacturing & Packing
8.	Dexchlorpheniramine Maleate BP/EP/USP	Manufacturing & Packing
9.	Diphenhydramine HCl EP/BP/USP	Manufacturing & Packing
10.	Dextromethorphan Hydrobromide BP/EP/USP	Manufacturing & Packing
11.	Hydroxocobalamin Acetate EP	Manufacturing & Packing
12.	Ketamine HCl BP/EP/USP	Manufacturing & Packing
13.	Mecobalamin USP/JP	Manufacturing & Packing
14.	Mepyramine Maleate BP/EP	Manufacturing & Packing
15.	Pentoxifylline EP/BP/USP	Manufacturing & Packing
16.	Pheniramine Maleate BP/EP/USP/JP	Manufacturing & Packing
17.	Pyrilamine Maleate USP	Manufacturing & Packing
18.	Riboflavin 5'-Phosphate Sodium USP	Manufacturing & Packing
19.	Riboflavin Sodium Phosphate BP/EP	Manufacturing & Packing
20.	Salbutamol Sulphate BP/EP	Manufacturing & Packing
21.	Theobromine EP/BP	Manufacturing & Packing
22.	Tramadol HCl EP/BP/USP	Manufacturing & Packing
23.	Quinine Sulphate BP/EP/IP	Manufacturing & Packing
24.	Nicorandil BP/IP/JP	Manufacturing & Packing
25.	Hydroxycobalamin Chloride Ph Eur	Manufacturing & Packing
26.	Hydroxycobalamin Sulfate BP/EP	Manufacturing & Packing
27.	Levosulbutamol Sulphate IP/IH	Manufacturing & Packing
28.	Hydroxycobalamin IP/USP	Manufacturing & Packing

ITEM(S) TWENTY EIGHT (28) ONLY

The Written Confirmation remains valid until: 02/07/2025

Signature

*[Handwritten Signature]*  
29 JUN 2022

Stamp of the authority and date





GOVERNMENT OF INDIA  
MINISTRY OF HEALTH & FAMILY WELFARE  
Central Drugs Standard Control Organization

Annexure-02

CERTIFICATE NO. :

WC-0218

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Supriya Lifescience Ltd.,  
A-5/2, Lote Parshuram Industrial Area,  
MIDC, Tal-Khed, Dist. Ratnagiri-415 722  
Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Brompheniramine Maleate BP/EP/USP	Manufacturing & Packing
2.	Dexbrompheniramine Maleate USP	Manufacturing & Packing
3.	Esketamine Hydrochloride BP/EP	Manufacturing & Packing

ITEM(S) Three (03) Only

This certificate is being issued subject to condition that the firm shall obtained NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substance for the purpose of export only, as the above mentioned active substance is not approved for manufacture for sale in India

The Written Confirmation remains valid until: 02/07/2025

Signature

29 JUN 2022

Stamp of the authority and date

